Tolerance of Adjuvant Ultrahypofractionated Whole-Breast Radiation Therapy Employing Moderately Hypofractionated Sequential Boost: A Single Institution Analysis
Early and intermediate results indicate that the treatment schedules, including the moderately hypofractionated boost, are safe and well tolerated, with acute toxicity rates comparable to those in the FAST-Forward trial. Although our study follow up is relatively short, our findings indicate that uhWBRT, with or without a moderately hypofractionated boost, is safe and well tolerated.
Authors
- Olga Unterkirhere (ORCID: https://orcid.org/0009-0000-8746-3814)
- Tino Streller
- Susanne Bucher
- David Jeller
- Philippe Logaritsch
- Peter Dubsky (ORCID: https://orcid.org/0000-0002-9566-0209)
- Gabriela Studer (ORCID: https://orcid.org/0000-0001-8780-7701)
- Christoph Glanzmann
Institutions
- University of Lucerne (CH)
- Luzerner Kantonsspital (CH)
- Breast Center (CH)
- Hirslanden Klinik St. Anna (CH)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.adro.2025.101756
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94